MRKR Quote, Financials, Valuation and Earnings

AIM ImmunoTech has a net margin of -162.11% compared to Marker Therapeutics, Inc.'s net margin of -10571.43%. Marker Therapeutics, Inc.'s return on equity of -103.04% beat AIM ImmunoTech's return on equity of -256.33%.

Marker Therapeutics, Inc. has a consensus price target of $7.33, signalling upside risk potential of 416.43%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Marker Therapeutics, Inc., analysts believe AIM ImmunoTech is more attractive than Marker Therapeutics, Inc..

Marker Therapeutics, Inc. has a beta of 1.350, which suggesting that the stock is 34.977% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.

Marker Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marker Therapeutics, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

Marker Therapeutics, Inc. quarterly revenues are $1.2M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Marker Therapeutics, Inc.'s net income of -$2M is higher than AIM ImmunoTech's net income of -$3.7M. Notably, Marker Therapeutics, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marker Therapeutics, Inc. is 3.85x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

Armata Pharmaceuticals, Inc. has a net margin of -162.11% compared to Marker Therapeutics, Inc.'s net margin of -2301.55%. Marker Therapeutics, Inc.'s return on equity of -103.04% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Marker Therapeutics, Inc. has a consensus price target of $7.33, signalling upside risk potential of 416.43%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 41.29%. Given that Marker Therapeutics, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Armata Pharmaceuticals, Inc..

Marker Therapeutics, Inc. has a beta of 1.350, which suggesting that the stock is 34.977% more volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.

Marker Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marker Therapeutics, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Marker Therapeutics, Inc. quarterly revenues are $1.2M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Marker Therapeutics, Inc.'s net income of -$2M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Marker Therapeutics, Inc.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marker Therapeutics, Inc. is 3.85x versus 52.84x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Neurocrine Biosciences, Inc. has a net margin of -162.11% compared to Marker Therapeutics, Inc.'s net margin of 26.36%. Marker Therapeutics, Inc.'s return on equity of -103.04% beat Neurocrine Biosciences, Inc.'s return on equity of 15.8%.

Marker Therapeutics, Inc. has a consensus price target of $7.33, signalling upside risk potential of 416.43%. On the other hand Neurocrine Biosciences, Inc. has an analysts' consensus of $179.96 which suggests that it could grow by 21.35%. Given that Marker Therapeutics, Inc. has higher upside potential than Neurocrine Biosciences, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Neurocrine Biosciences, Inc..

Marker Therapeutics, Inc. has a beta of 1.350, which suggesting that the stock is 34.977% more volatile than S&P 500. In comparison Neurocrine Biosciences, Inc. has a beta of 0.273, suggesting its less volatile than the S&P 500 by 72.654%.

Marker Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neurocrine Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marker Therapeutics, Inc. pays -- of its earnings as a dividend. Neurocrine Biosciences, Inc. pays out -- of its earnings as a dividend.

Marker Therapeutics, Inc. quarterly revenues are $1.2M, which are smaller than Neurocrine Biosciences, Inc. quarterly revenues of $794.9M. Marker Therapeutics, Inc.'s net income of -$2M is lower than Neurocrine Biosciences, Inc.'s net income of $209.5M. Notably, Marker Therapeutics, Inc.'s price-to-earnings ratio is -- while Neurocrine Biosciences, Inc.'s PE ratio is 35.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marker Therapeutics, Inc. is 3.85x versus 5.62x for Neurocrine Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -162.11% compared to Marker Therapeutics, Inc.'s net margin of 13.19%. Marker Therapeutics, Inc.'s return on equity of -103.04% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Marker Therapeutics, Inc. has a consensus price target of $7.33, signalling upside risk potential of 416.43%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 514.53%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Marker Therapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Marker Therapeutics, Inc..

Marker Therapeutics, Inc. has a beta of 1.350, which suggesting that the stock is 34.977% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Marker Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marker Therapeutics, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Marker Therapeutics, Inc. quarterly revenues are $1.2M, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Marker Therapeutics, Inc.'s net income of -$2M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Marker Therapeutics, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 25.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marker Therapeutics, Inc. is 3.85x versus 2.28x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.